Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Debt-to-Equity : 1.11 (As of Mar. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Spectrum Pharmaceuticals Debt-to-Equity?

Spectrum Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.77 Mil. Spectrum Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $28.84 Mil. Spectrum Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $26.81 Mil. Spectrum Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2023 was 1.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Spectrum Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

SPPI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.18 Max: 1.11
Current: 1.11

During the past 13 years, the highest Debt-to-Equity Ratio of Spectrum Pharmaceuticals was 1.11. The lowest was 0.01. And the median was 0.18.

SPPI's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs SPPI: 1.11

Spectrum Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Spectrum Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectrum Pharmaceuticals Debt-to-Equity Chart

Spectrum Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.03

1.06

Spectrum Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.02	0.82	1.06	1.11

Competitive Comparison of Spectrum Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Spectrum Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spectrum Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spectrum Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Spectrum Pharmaceuticals's Debt-to-Equity falls into.

Spectrum Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Spectrum Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.761	+	28.666)	/	27.888
	=	1.06

Spectrum Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.771	+	28.84)	/	26.805
	=	1.10

Spectrum Pharmaceuticals (NAS:SPPI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Spectrum Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Spectrum Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spectrum Pharmaceuticals Inc (NAS:SPPI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Pilot House - Lewis Wharf, 2 Atlantic Avenue, 6th Floor, Boston, MA, USA, 02110

Website

https://www.sppirx.com

Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.

Executives

Juhyun Lim	director	11500 S. EASTERN AVE., SUITE 220, HENDERSON NV 89052
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Brittany Bradrick	director	C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Nora Brennan	officer: See Remarks	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Keith M Mcgahan	officer: Chief Legal Officer	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Thomas J Riga	director, officer: CEO & President	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Francois Lebel	officer: Chief Medical Officer	4100 LEXINGTO AVE N, ARDEN HILLS MN 55126-2998
Dolatrai Vyas	director	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Kurt A Gustafson	officer: EVP & Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Joseph W. Turgeon	officer: Chief Commercial Officer	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Elizabeth Czerepak	director	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Maida Anthony E Iii	director	157 TECHNOLOGY DR, IRVINE CA 92618
Stuart Mitchell Krassner	director	157 TEHCNOLOGY DRIVE, IRVINE CA 92618